Abstract: Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.

Abstract: The present invention provides a tropoelastin-derived polypeptide and an elastic composite biocompatible material comprising the polypeptide. The object of the invention is also a method for the synthesis of such a biocompatible material, a cell culture support comprising such a biocompatible material and the use of this material, in particular in the biological and medical field, in particular for cell culture and tissue regeneration.

Abstract: The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the ? chain of the interleukine 3 receptor, or IL-3R?). The present invention also relates to methods of using such CD123-binding molecules for diagnosing and treating diseases, such as B-cell malignancies.

Abstract: The present invention provides peptidic TGF-? antagonists capable of inhibiting TGF-? signaling and disrupting the biochemical events that promote fibrosis and the epithelial-mesenchymal transition. The peptidic TGF-? antagonist may contain from 11 to 28 amino acid residues (for instance, may consist of from 12 to 16 amino acid residues) and may have the following structure (II): NH2? ETWIWLDTNMG-Xaa1-Y?COOH (II) wherein Xaa1 is any amino acid and Y is a peptide having from 0 to 9 amino acids. The peptidic TGF-? antagonists can advantageously be used for the prevention, treatment, and/or alleviation of the symptoms of a condition associated with an increase in TGF-? activity, including fibrosis (such as fibrosis of the skin, liver, lungs, and heart, among others) and cancer (including various carcinomas, such as squamous cell carcinoma, sarcomas, and metastatic cancers).

Abstract: CsChrimson light-activated ion channel polypeptides, their encoding polynucleotides, and variants thereof are provided. Methods of introducing and using CsChrimson light activated ion channels and variants thereof for to alter cell activity and function are also provided.

Abstract: The invention describes peptide ligands specific for human plasma Kallikrein.

Abstract: This document features method related to variants in the Inverted Formin 2 (INF2) gene that are associated with susceptibility to focal segmental glomerulosclerosis (FSGS). For example, methods of using such variants for risk assessment and for diagnosing and optimizing treatment of FSGS are provided.

Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.

Abstract: Disclosed are a conotoxin polypeptide ?-CPTx-bt105, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the present invention consists of 16 amino acids, has a molecular weight of 1626.62 daltons, and has the full sequence GICCVDDTCTTHSGCL (SEQ. ID NO. 1).

Abstract: Disclosed are novel peptides with adhesive properties to various materials of biological or non-biological origins.

Abstract: This disclosure provides compositions and methods for treating or preventing cardiac or vascular toxicity in a subject receiving a chemotherapeutic agent, where the cardiac or vascular toxicity is associated with administration of the chemotherapeutic agent. Also provided are compositions and methods for treating or preventing endothelial dysfunction and for modulating endothelial function and oxidative stress.

Abstract: This document provides polypeptide inhibitors of Smad3 polypeptide activities. For example, methods and materials for using polypeptides (e.g., polypeptides designed to include both a cell penetrating amino acid sequence and an amino acid segment of a SH3 domain of a SNX9 polypeptide) to inhibit one or more Smad3 polypeptide activities are provided. This document also provides methods and materials for using RNA interference to treat a disease (e.g., a fibrotic disease) in a mammal (e.g., a human).

Abstract: Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.

Abstract: Disclosed are a conotoxin polypeptide ?-CPTx-bt102, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the present invention consists of 15 amino acids, has a molecular weight of 1660.61 daltons, and has the full sequence RCRCEQTCGTCVPCC (SEQ. ID NO. 1).

Abstract: A protein adhesive of a novel sequence is disclosed. The protein adhesive according to the present disclosures enables adhesion between two non-biological materials or between a non-biological material and a biological material, thereby being applicable to various fields.

Abstract: The invention belongs to the technical field of polypeptide preparation methods, and in particular relates to a preparation method of a liraglutide intermediate polypeptide GLP-1 (7-37). In the preparation method, main steps include constructing recombinant liraglutide engineered bacteria via E. coli to induce expression of a liraglutide intermediate fusion protein in the form of inclusion bodies, and performing denaturation, renaturation, enzyme digestion, separation and purification to obtain the liraglutide intermediate polypeptide GLP-1 (7-37). The invention alters expression pattern into the expression of the intracellular insoluble inclusion bodies by changing a signal peptide of the recombinant sequence to increase significantly expression level. The liraglutide intermediate polypeptide prepared by the invention has a purity up to 87% or more and a yield of more than 85%.

Abstract: Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

Abstract: The invention describes peptide ligands specific for human plasma Kallikrein.

Abstract: The present invention relates to a factor VII composition having a substantially homogeneous isoelectric point and to a method for formulating such a composition. The present invention also relates to the therapeutic use of a factor VII composition having a substantially homogeneous isoelectric point.

Abstract: Disclosed are a conotoxin polypeptide ?-CPTx-bt103, a method for preparation thereof, and an application thereof. The conotoxin polypeptide of the present invention consists of 29 amino acids, has a molecular weight of 3141.43 daltons, and has the full sequence RTNCGETCLKDEQCVGACQICVPSQLKCL (SEQ ID NO. 1).